Friday, July 10, 2026
🇺🇸 FDA

pharma · Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) · Advanced Solid Tumor

Daiichi Sankyo US

Daiichi Sankyo

Daiichi Sankyo US clinical programs — 58 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US HQ
4,386 Employees
NMPA registrant Type
Company details
Status
Public
HQ
211 Mt. Airy Road Basking Ridge, Basking Ridge, NJ 07920, US
Employees
4,386
Programs
58
Drugs
66
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Daiichi Sankyo US projects

58 ClinicalTrials.gov programs sponsored by Daiichi Sankyo US.

Daiichi Sankyo US has 58 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

58 programs

Clinical programs

Page 1 of 2

  1. AC220-168

    Daiichi Sankyo

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  2. CS-3150

    Daiichi Sankyo

    Hypertension

    phase 3 small molecule completed

    1 trial

  3. DS-8201a

    Daiichi Sankyo

    Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors

    phase 3 small molecule active

    1 trial

  4. DS1062-328

    Daiichi Sankyo

    Locally Advanced or Metastatic Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

  5. DS1062-A-U304

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  6. DS6000-109

    Daiichi Sankyo

    Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer

    phase 3 small molecule active

    1 trial

  7. DS7300-188

    Daiichi Sankyo

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  8. DS7300-202

    Daiichi Sankyo

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 small molecule active

    1 trial

  9. DS8201-724

    Daiichi Sankyo

    Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer

    phase 3 small molecule active

    1 trial

  10. DS8201-772

    Daiichi Sankyo

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  11. DS8201-793

    Daiichi Sankyo

    Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  12. DS8201-854

    Daiichi Sankyo

    HER2-expressing endometrial cancer (IHC 3+/2+)

    phase 3 small molecule active

    1 trial

  13. DS8201-A-U302

    Daiichi Sankyo

    Metastatic breast cancer

    phase 3 small molecule active

    1 trial

  14. DS8201-A-U305

    Daiichi Sankyo

    High-Risk HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  15. DS8201-A-U306

    Daiichi Sankyo

    Metastatic Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  16. Datopotamab deruxtecan, DOCETAXEL

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  17. Edoxaban

    Daiichi Sankyo

    Cardiac Disease

    phase 3 small molecule completed

    1 trial

  18. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  19. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  20. Trastuzumab Deruxtecan

    Daiichi Sankyo

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  21. U31402-A-U301

    Daiichi Sankyo

    Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  22. edoxaban tosylate(DU-176b)

    Daiichi Sankyo

    Venous Thromboembolism

    phase 3 small molecule completed

    1 trial

  23. 10mg DS-8500a tablet

    Daiichi Sankyo

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  24. CS-3150

    Daiichi Sankyo

    Diabetic Nephropathy

    phase 2 small molecule completed

    1 trial

  25. DS-1062a

    Daiichi Sankyo

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  26. DS-3939a

    Daiichi Sankyo

    Metastatic Solid Tumor, Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  27. DS-5141b

    Daiichi Sankyo

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  28. DS-8201a

    Daiichi Sankyo

    Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer

    phase 2 small molecule active

    1 trial

  29. DS3201-330

    Daiichi Sankyo

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  30. DS7300-189

    Daiichi Sankyo

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  31. Datopotamab deruxtecan

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  32. EPCORITAMAB, RITUXIMAB

    Daiichi Sankyo

    Hematological Malignancies

    phase 2 small molecule active

    1 trial

  33. HER3-DXd

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  34. Ifinatamab deruxtecan

    Daiichi Sankyo

    Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  35. Ifinatamab deruxtecan

    Daiichi Sankyo

    Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)

    phase 2 small molecule active

    1 trial

  36. Patritumab deruxtecan

    Daiichi Sankyo

    Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  37. Patritumab deruxtecan

    Daiichi Sankyo

    Locally Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  38. Quizartinib

    Daiichi Sankyo

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  39. Raludotatug Deruxtecan

    Daiichi Sankyo

    Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

    phase 2 small molecule active

    1 trial

  40. Valemetostat Tosylate, Valemetostat Tosylate

    Daiichi Sankyo

    Relapsed/Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  41. olmesartan medoxomil

    Daiichi Sankyo

    Chronic Glomerulonephritis

    phase 2 small molecule completed

    1 trial

  42. DS-1205c

    Daiichi Sankyo

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 small molecule terminated

    1 trial

  43. DS1062-A-U102

    Daiichi Sankyo

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  44. DS3201-324

    Daiichi Sankyo

    This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.

    phase 1 small molecule active

    1 trial

  45. DS8201-A-U106

    Daiichi Sankyo

    Locally advanced/metastatic breast or non-small cell lung cancer

    phase 1 other active

    1 trial

  46. DSE-BMP-0001-CIS-MA

    Daiichi Sankyo

    No medical condition.

    phase 1 other active

    1 trial

  47. DSE-BMP-0002-CIS-MA

    Daiichi Sankyo

    No medical condition

    phase 1 other active

    1 trial

  48. DSE-BMP-0003-CIS-MA

    Daiichi Sankyo

    No medical condition.

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Daiichi Sankyo US have?

58 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.